Tonix Pharmaceuticals Announces Proposed Public Offering

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock or pre-funded warrants, subject to market conditions, with no assurance on the completion or terms of the offering [9]. Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing, and commercializing therapeutics for human diseases, particularly in central nervous system (CNS) disorders [5]. - The company aims to submit a New Drug Application (NDA) for its product candidate Tonmya™ for fibromyalgia management in the second half of 2024, following two statistically significant Phase 3 studies [5][6]. - Tonix's product portfolio includes TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection and autoimmune diseases [5]. Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and preparation of the new drug application for Tonmya™ [3].